𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I study of docetaxel and topotecan in patients with solid tumors

✍ Scribed by Katherine H. Tkaczuk; William C. Zamboni; Nancy S. Tait; Barry R. Meisenberg; L. Austin Doyle; Martin J. Edelman; Petr F. Hausner; Merrill J. Egorin; David A. Van Echo

Publisher
Springer
Year
2000
Tongue
English
Weight
103 KB
Volume
46
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase I evaluation of docetaxel and topo
Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors
✍ Anne S. Tsao; Dong M. Shin; J. Lynn Palmer; Jin S. Lee; Bonnie S. Glisson πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 79 KB

## Abstract ## BACKGROUND The authors administered a combination of docetaxel and topotecan with granulocyte–colony‐stimulating factor (G‐CSF) support in a Phase I study to define the maximum tolerated dose (MTD) of this regimen. ## METHODS Patients with advanced‐stage solid tumors were eligible

A phase I study of gemcitabine and docet
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors
✍ David P. Ryan; Thomas J. Lynch; Michael L. Grossbard; Michael V. Seiden; Charles πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 70 KB πŸ‘ 2 views

A Phase I study was initiated to determine the maximum tolerated dose of weekly gemcitabine combined with monthly, fixed-dose docetaxel. ## METHODS. Patients with metastatic solid tumors were treated with docetaxel, 60 mg/m 2 , on Day 1 every 28 days. Gemcitabine was administered on Days 1, 8, and